Research Use Only

All products are for in vitro research and laboratory use only.

These products are not approved by the FDA and are not intended for human or veterinary use, consumption, or therapeutic application.

By entering you confirm you are a qualified researcher or licensed professional, 18 years or older.

Skip to content
SustainPeptides

SS-31 and Mitochondrial Research: A Study Breakdown

← Research Hub

Research summary · 10 min read · 12 references

Editorial note: SS-31 has a strong preclinical literature and some Phase I/II human trial data in cardiovascular and renal indications. Human efficacy has not been established in Phase III trials. Summarized findings are primarily preclinical unless noted.

What Is SS-31?

SS-31 (also known as Elamipretide, MTP-131, or Bendavia) is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH₂, where Dmt is 2,6-dimethyltyrosine. It was developed by Hazel Szeto and Peter Schiller — hence the name Szeto-Schiller peptide (SS-peptide). The alternating aromatic/cationic residue pattern enables membrane association and selective accumulation in the inner mitochondrial membrane (IMM), reaching concentrations up to 1,000-fold greater than the cytoplasm.

The Cardiolipin Interaction Mechanism

Cardiolipin (CL) is a unique phospholipid found almost exclusively in the IMM, constituting approximately 20% of its lipid composition. It plays essential structural and functional roles in organizing the respiratory chain supercomplexes (Complexes I-IV) and ATP synthase, maintaining cristae morphology, and anchoring cytochrome c in its electron carrier conformation.

Under conditions of mitochondrial stress (ischemia, aging, metabolic disease), cardiolipin undergoes peroxidation by reactive oxygen species (ROS). Peroxidized cardiolipin cannot maintain its structural role and causes cytochrome c to dissociate and adopt a peroxidase activity, generating further ROS and ultimately triggering apoptosis via cytochrome c release to the cytoplasm.

Szeto (2014) — Pharmacological Review of the Cardiolipin Interaction

In her comprehensive review (Pharmacological Reviews, 2014), Szeto established the cardiolipin interaction as the central mechanism of SS-31 action. SS-31 binds cardiolipin selectively via electrostatic and hydrophobic interactions, inhibiting its peroxidation by preventing cytochrome c peroxidase activity. Critically, SS-31 does not directly scavenge ROS — its antioxidant effect is indirect, achieved by stabilizing the electron transport chain to reduce electron leak and ROS production at the source.

Ischemia-Reperfusion Studies

Cho et al. (2007) — Cardiac Ischemia-Reperfusion

In a rat cardiac ischemia-reperfusion injury model, SS-31 administered before reperfusion significantly reduced infarct size (by approximately 40% versus vehicle), preserved cardiac function, and reduced cytochrome c release versus controls. The effect was observed with doses as low as 1 nmol/kg intravenously, reflecting the high mitochondrial accumulation efficiency of the peptide.

Renal Ischemia Models

Multiple studies from the Bhatt, Szeto, and Bhatt labs report SS-31 protection in renal ischemia-reperfusion models, demonstrating preserved tubular cell viability, reduced serum creatinine elevation, and improved GFR recovery following ischemic insult. These findings led to Phase I/II clinical investigation of Elamipretide in ischemic renal disease contexts.

Aging and Bioenergetic Studies

Siegel et al. (2013) — Aged Rat Skeletal Muscle

In aged (24-month) rats versus young (5-month) controls, SS-31 treatment rapidly (within 1 hour) restored mitochondrial oxygen consumption rate (OCR), membrane potential, and ATP production rates in skeletal muscle cells to levels approaching those of young controls. This restoration was associated with improved cristae morphology on electron microscopy, consistent with SS-31 normalizing cardiolipin-dependent cristae architecture.

Human Clinical Data (Phase II)

Elamipretide (SS-31) has been tested in Phase II clinical trials for heart failure with preserved ejection fraction (HFpEF) and for mitochondrial myopathy. The PROGRESS-HFpEF trial (2020) did not meet its primary endpoint (change in 6-minute walk distance) versus placebo after 28 weeks of subcutaneous administration, though post-hoc analyses suggested possible benefit in subgroups with specific echocardiographic phenotypes. A Phase II trial in primary mitochondrial myopathy (MMPOWER-3) also did not meet its primary endpoint. These negative Phase II results in human trials contrast with the strong preclinical data and highlight the challenge of translating mitochondrial biology from rodent models to human disease.

Key Limitations

  • Phase II human trial failures: Despite robust preclinical data, Phase II trials in HFpEF and mitochondrial myopathy did not meet primary endpoints — a significant translational gap.
  • Species difference in cardiolipin composition: Cardiolipin fatty acid composition differs between rodent and human tissues, potentially affecting SS-31 interaction kinetics.
  • Bioavailability and route: Systemic delivery of SS-31 to specific tissues with mitochondrial dysfunction in humans presents pharmacokinetic challenges not present in controlled animal studies.

Summary

SS-31 has a mechanistically rigorous preclinical literature centered on cardiolipin interaction, inhibition of cytochrome c peroxidase activity, and restoration of electron transport chain efficiency in ischemia and aging models. The translation to human efficacy has been challenged by Phase II trial failures in HFpEF and mitochondrial myopathy — an important counterpoint to the compelling preclinical data that makes SS-31 a valuable but cautionary case study in mitochondrial pharmacology research.